Article Text

Download PDFPDF

Ewing’s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities
  1. S A Burchill
  1. Correspondence to:
 Dr S A Burchill, Candlelighter’s Children’s Cancer Research Laboratory, Cancer Research UK Clinical Centre, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK;
 s.a.burchill{at}leeds.ac.uk

Abstract

The identification of the non-random chromosome rearrangements between the EWS gene on chromosome 22q12 and members of the ETS gene family in Ewing’s sarcoma, peripheral primitive neuroectodermal tumour, Askin tumour, and neuroepithelioma has been a key advance in understanding their common histogenesis and defining the Ewing’s sarcoma family of tumours (ESFT). In addition to improvements in diagnosis and potentially the stratification of patients for risk, biological investigations of these gene fusions may define targets for much needed therapeutic strategies to eliminate minimal residual disease or metastatic disease. Insight into their relation with other oncogenic events in ESFT will advance risk group analysis and ultimately may improve clinical management and survival for patients with this disease.

  • Ewing’s sarcoma
  • diagnosis
  • prognosis
  • treatment
  • translocations
  • ESFT, Ewing’s sarcoma family of tumours
  • Euro EWING 99, European Ewing tumour working initiative of national groups 99
  • FISH, fluorescent in situ hybridisation
  • pPNET, peripheral primitive neuroectodermal tumour
  • RT-PCR, reverse transcriptase polymerase chain reaction
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.